GlassScriptPhysician profile
Jackie Correro
NPI 1700285491
$3,185.37
in general payments reported to CMS, 2019-2025
28 companies · $684 in 2025
The $684 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $893 · 2023: $539 · 2024: $850 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $773.64 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.01 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $237.70 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $199.66 | 2025 | |
| Amgen INC. | $198.10 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $188.17 | 2021-2025 | Verquvo, Winrevair |
| Abbott Laboratories | $145.08 | 2022 | |
| Alnylam Pharmaceuticals INC. | $143.61 | 2022-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $141.80 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $116.56 | 2022-2025 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.85 | 2024-2025 | Lifevest |
| Pfizer INC. | $100.05 | 2022-2024 | |
| Boston Scientific Corporation | $84.29 | 2022-2025 | Watchman Flx |
| Philips North America LLC | $65.26 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $61.83 | 2024-2025 | Camzyos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $55.73 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.82 | 2023-2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $40.08 | 2022-2024 | |
| Akcea Therapeutics, INC. | $31.70 | 2021 | |
| Daxor Corporation | $20.51 | 2022 | |
| Cvrx, INC. | $20.48 | 2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $18.52 | 2024 | |
| Impulse Dynamics (USA) INC. | $17.85 | 2023 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $16.84 | 2023 | Livalo |
| Silk Road Medical, INC. | $16.28 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Kiniksa Pharmaceuticals International, Plc | $13.67 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $13.46 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $10.82 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Correro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.